- Home
- PIRS vs TNXP Comparison
PIRS vs TNXP Comparison
Compare PIRS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIRS
- TNXP
- Stock Information
- Founded
- PIRS 2001
- TNXP 2007
- Country
- PIRS United States
- TNXP United States
- Employees
- PIRS N/A
- TNXP N/A
- Industry
- PIRS Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- PIRS Health Care
- TNXP Health Care
- Exchange
- PIRS Nasdaq
- TNXP Nasdaq
- Market Cap
- PIRS 22.4M
- TNXP 19.5M
- IPO Year
- PIRS N/A
- TNXP N/A
- Fundamental
- Price
- PIRS $15.93
- TNXP $0.20
- Analyst Decision
- PIRS
- TNXP Strong Buy
- Analyst Count
- PIRS 0
- TNXP 2
- Target Price
- PIRS N/A
- TNXP $53.50
- AVG Volume (30 Days)
- PIRS 37.6K
- TNXP 51.5M
- Earning Date
- PIRS 11-13-2024
- TNXP 11-12-2024
- Dividend Yield
- PIRS N/A
- TNXP N/A
- EPS Growth
- PIRS N/A
- TNXP N/A
- EPS
- PIRS N/A
- TNXP N/A
- Revenue
- PIRS $1,352,000.00
- TNXP $11,291,000.00
- Revenue This Year
- PIRS N/A
- TNXP $62.53
- Revenue Next Year
- PIRS N/A
- TNXP $26.17
- P/E Ratio
- PIRS N/A
- TNXP N/A
- Revenue Growth
- PIRS N/A
- TNXP 183.05
- 52 Week Low
- PIRS $6.20
- TNXP $0.12
- 52 Week High
- PIRS $22.32
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- PIRS 43.29
- TNXP 69.43
- Support Level
- PIRS $15.15
- TNXP $0.13
- Resistance Level
- PIRS $16.97
- TNXP $0.28
- Average True Range (ATR)
- PIRS 0.72
- TNXP 0.02
- MACD
- PIRS -0.08
- TNXP 0.01
- Stochastic Oscillator
- PIRS 30.75
- TNXP 49.47
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.